StreetInsider.com News Articles

Piper Sandler: 'We believe investors should start to look at and build positions in Orchestra BioMed (OBIO)'

Thu, 15 Oct 2026 08:58:04 -0400

Piper Sandler analyst Matt O'Brien reiterated an Overweight rating and $12.00 price target on Orchestra BioMed Inc. (NASDAQ: OBIO).

The analyst commented: "We wanted to highlight OBIO as a name that could drive significant value creation for shareholders in the coming quarters. Its key AVIM therapy to treat hypertension patients recently completed enrollment in its pivotal trial, with a data release in Q2’27 (likely HRS). If positive, which we believe it will be, it could lead to approval for this unique therapy in early ’28 (though we believe the stock will move on the data). AVIM revenue (global) to OBIO could

H.C. Wainwright Reiterates Buy Rating on Orchestra BioMed Inc. (OBIO)

Mon, 05 Oct 2026 06:49:47 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $10.00 price target on Orchestra BioMed Inc. (NASDAQ: OBIO).

The analyst commented: "Yesterday, Orchestra Biomed announced that the BACKBEAT global pivotal trial of the atrioventricular interval modulation (AVIM) therapy in pacemaker-indicated patients with uncontrolled hypertension has surpassed full enrollment target of 316 randomized patients. As of September 30, 2026, 330 patients have been randomized at 81 sites across 13 countries. Approved by the FDA, the trial protocol specifies 284 evaluable randomized subjects for the primary endpoint analysis with a total enrollment target of 316 patients to account for potential loss to

Form 4 Orchestra BioMed Holding For: Oct 01 Filed by: Sherman Darren

Fri, 02 Oct 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20261002/27142860.html

Form 144 Orchestra BioMed Holding Filed by: Sherman Darren

Thu, 01 Oct 2026 10:37:00 -0400

si-local-file:///var/storage/secattach/20261001/27133495.html

Form 8-K Orchestra BioMed Holding For: Oct 01

Thu, 01 Oct 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20261001/27131989.html

Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy

Thu, 01 Oct 2026 08:00:00 -0400

330 patients randomized as of September 30, 2026, surpassing full trial enrollment target
Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027
Data expected to support future marketing application submissions by Medtronic to the FDA and other global regulatory agencies

NEW HOPE, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading medical device companies, today announced that it

Orchestra BioMed Exceeds Full Enrollment Target in the BACKBEAT Global Pivotal Trial of AVIM Therapy

Thu, 01 Oct 2026 08:00:00 -0400

330 patients randomized as of September 30, 2026, surpassing full trial enrollment target
Company reiterates prior guidance: primary endpoint data to be submitted for late-breaking presentation consideration at a major cardiovascular conference in Q2 2027
Data expected to support future marketing application submissions by Medtronic to the FDA and other global regulatory agencies

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

Wed, 16 Sep 2026 08:30:00 -0400

Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyond

NEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that its investigational Atrioventricular Interval Modulation Therapy ("AVIM Therapy") will be featured in two sessions at HRX Live 2026 -- the Heart Rhythm Society's annual innovation-focused meeting taking place September 18-20, 2026, in Atlanta,

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

Wed, 16 Sep 2026 08:30:00 -0400

Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyond

Orchestra BioMed receives $6.1M milestone payment from Vivasure deal

Tue, 15 Sep 2026 08:30:36 -0400

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced it received a $6.1 million milestone payment on Sept. 14, 2026, stemming from the acquisition of Vivasure Medical Limited by Haemonetics Corporation (NYSE: HAE).

The payment represents the first milestone installment tied to the transaction and follows an approximately $5 million upfront payment received in January 2026. Combined, the two payments bring total cash proceeds received by Orchestra BioMed to approximately $11 million.

Haemonetics completed its acquisition of Vivasure, an Ireland-based medical device company focused on percutaneous vessel closure technology, on Jan. 9, 2026. Vivasure had been a strategic holding of Orchestra BioMed since the

Orchestra BioMed receives $6.1M milestone payment from Vivasure deal

Tue, 15 Sep 2026 08:30:36 -0400

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Tue, 15 Sep 2026 08:30:00 -0400

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Tue, 15 Sep 2026 08:30:00 -0400

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Tue, 15 Sep 2026 08:30:00 -0400

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

Orchestra BioMed Receives $6.1 Million Milestone Payment from Acquisition of Vivasure by Haemonetics

Tue, 15 Sep 2026 08:30:00 -0400

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 million
Company remains eligible for up to approximately $10 million in additional proceeds through future revenue earnouts
Monetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships

Orchestra BioMed Inc. (OBIO) PT Raised to $11 at B.Riley

Tue, 15 Sep 2026 08:17:20 -0400

B.Riley analyst Kyle Bauser raised the price target on Orchestra BioMed Inc. (NASDAQ: OBIO) to $11.00 (from $10.00) while maintaining a Buy rating.

Form 4 Orchestra BioMed Holding For: Sep 10 Filed by: Hochman David P

Fri, 11 Sep 2026 18:12:00 -0400

si-local-file:///var/storage/secattach/20260911/27053840.html

BTIG Upgrades Orchestra BioMed Inc. (OBIO) to Buy

Thu, 10 Sep 2026 05:32:47 -0400

(Updated - September 10, 2026 5:32 AM EDT)

BTIG analyst Marie Thibault upgraded Orchestra BioMed Inc. (NASDAQ: OBIO) from Neutral to Buy with a price target of $10.00.

The analyst comments "We are upgrading our recommendation on Orchestra BioMed from Neutral to Buy and setting a $10 PT. We have become more constructive on the stock following recent management commentary detailing that the BACKBEAT trial is set to finish enrollment on schedule around the end of Q3. We had previously felt that hitting timelines, securing non-dilutive financing, and establishing a near-term catalyst pathway were the key criteria for an upgrade. OBIO has

BTIG Upgrades Orchestra BioMed Inc. (OBIO) to Buy

Thu, 10 Sep 2026 05:32:47 -0400

(Updated - September 10, 2026 5:32 AM EDT)

BTIG analyst Marie Thibault upgraded Orchestra BioMed Inc. (NASDAQ: OBIO) from Neutral to Buy with a price target of $10.00.

BTIG Upgrades Orchestra BioMed Inc. (OBIO) to Buy

Thu, 10 Sep 2026 05:32:47 -0400

(Updated - September 10, 2026 5:32 AM EDT)

BTIG analyst Marie Thibault upgraded Orchestra BioMed Inc. (NASDAQ: OBIO) from Neutral to Buy with a price target of $10.00.

BTIG Upgrades Orchestra BioMed Inc. (OBIO) to Buy

Thu, 10 Sep 2026 05:32:47 -0400

(Updated - September 10, 2026 5:32 AM EDT)

BTIG analyst Marie Thibault upgraded Orchestra BioMed Inc. (NASDAQ: OBIO) from Neutral to Buy with a price target of $10.00.

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:05:00 -0400

NEW HOPE, Pa., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on September 1, 2026, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 133,000 shares of the Company’s common stock to seven newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:05:00 -0400

Form 4 Orchestra BioMed Holding For: Aug 26 Filed by: Taylor Andrew Lawrence

Fri, 28 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260828/26998160.html

Form 4 Orchestra BioMed Holding For: Aug 26 Filed by: Taylor Andrew Lawrence

Fri, 28 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260828/26998160.html